Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nature - 16 Dec 2010

Nazarian Ramin, Shi Hubing, Wang Qi, Kong Xiangju, Koya Richard C, Lee Hane, Chen Zugen, Lee Mi-Kyung, Attar Narsis, Sazegar Hooman, Chodon Thinle, Nelson Stanley F, McArthur Grant, Sosman Jeffrey A, Ribas Antoni, Lo Roger S

Abstract excerpt

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumour response rate among patients with B-RAF(V600E)-positive melanomas, but acquired drug resistance frequently develops after initial responses. Hypotheses for mechanisms of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, ras
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mitogen-Activated Protein Kinase Kinases

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 21107323
DOI: 10.1038/nature09626
PMCID: PMC3143360

Genes

BRAF
NRAS
PDGFRB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.PMID 21107323Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Semantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Adaptive resistance to <scp>RAF</scp> inhibitors in melanomaSemantic proximity Read ↗

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant MelanomaSemantic proximity Read ↗

C-RAF mutations confer resistance to RAF inhibitors.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.Semantic proximity Read ↗

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.